Entity

Time filter

Source Type

Waltham, MA, United States

Patent
Proteon Therapeutics Inc. | Date: 2013-08-02

The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.


Patent
Proteon Therapeutics Inc. | Date: 2010-04-21

Methods are described for dilating biological conduits by removing elastin and remodeling collagens in the wall of the conduit. Methods include the use of agents that increase the release of endogenous elastase and collagenase in the wall of the conduit, either by cells that are normally present in the wall of the conduit or by inflammatory cells that are attracted to the conduit, thereby providing additional conduit dilation. Methods also include the use of agents that increase conduit wall permeability and expose elastin and collagen fibers. Methods also include removing components of the extracellular matrix of arteries and veins leading to an inhibition of intimal hyperplasia in the wall of the vessels by decreasing biomechanical stimuli directed toward the cells in the wall of the vessel. Methods further include the use of agent that degrade microfibers, in addition to elastin, in order to decrease the resynthesis of elastin. Methods also include the use of agent that stabilize the diameter of aneurysmal arteries by blocking cell surface receptors in the wall of the aneurysmal artery that are important in the recruitment of inflammatory cells.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 99.51K | Year: 2005

DESCRIPTION (provided by applicant): Angioplasty has proved to be an effective treatment for vascular obstruction. After initial success, however, restenosis occurs at many angioplasty sites, leading to further treatment, health care expenses and human suffering. A critical need exists to prolong the patency of angioplasty sites. The goal of the proposed work is to test a novel therapeutic agent in the rapid and local dilation of angioplasty sites beyond the diameter of the balloon itself. This proposal describes key proof-of-concept studies investigating the efficacy and safety of the therapeutic agent. The goals of the proposal are to demonstrate immediate and persistent gains in vessel lumen diameter with direct intramural treatment during angioplasty and to determine the effects of treatment on vessel tensile strength. Completion of the specific aims and-successful achievement of milestone criteria will allow the project to progress to Phase II, which will consist of pre-clinical studies with the goal of submitting an Investigational New Drug application. In Phase III, clinical studies will be undertaken with the ultimate goal of commercializing a new therapeutic agent to prevent restenosis and occlusion following angioplasty, improving patient quality of life and reducing public health care burdens.


Patent
Proteon Therapeutics Inc. | Date: 2013-08-30

The invention provides methods to for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.


Patent
Proteon Therapeutics Inc. | Date: 2014-08-21

The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.

Discover hidden collaborations